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ABSTRACT
OBJECTIVE: Our goal was to evaluate whether a normal ultrasound following a 
positive triple marker serum screen reduces the risk of having a  trisomy 18 fetus 
to a level that is less than the procedure-related risk for amniocentesis. STUDY 
DESIGN: A nonrandomized, non-concurrent cohort chart review was performed 
o f all women who screened positive (risk > 1:250) for trisomy 18 by triple marker 
serum testing through Spectrum Health Downtown Genetic Screening Program 
from June 1996 through September 1999. O f the 13,618 serum samples screened, 
158 were identified as being at an increased risk for trisomy 18. Pediatric 
outcome was obtained through office documentation, review o f  birth records, or 
phone contact with the mother. RESULTS: Four cases o f trisomy 18 were 
identified and all had abnormalities on ultrasound. CONCLUSION: The 
presence of normal ultrasound was not associated with significant increased risk 
for trisomy 18. In this population, amniocentesis is not justified.
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CHAPTER ONE 
INTRODUCTION
Background to Problem 
Prenatal screening has become an important part of the care o f pregnant 
women in our society. The standard o f care today includes routine testing for 
fetal anomalies in conjunction with regularly scheduled obstetric visits. Routine 
testing means that the available screening is offered to the patient by her 
practitioner as part o f  antenatal care. The patient then has the option to either 
accept or decline such testing after being informed o f its risks and benefits.' 
Prenatal screening allows parents to make informed decisions regarding the care 
o f their baby.'
One specific use o f prenatal screening is the detection o f certain 
chromosomal abnormalities such as trisomy 21 and trisomy 18. The current 
methods used for determining the fetal anomalies associated with trisomy 21 and 
trisomy 18 are: the maternal triple marker serum screen; ultrasonography; and 
amniocentesis. The triple marker screen is offered to the pregnant woman as a 
first option in screening for chromosomal aberrations. This screen in typically 
offered between 15 and 22 weeks gestation. The second trimester triple marker 
serum screen consists of: maternal P-human chorionic gonadotropin (P-hCG); 
unconjugated estriol; and alpha fetoprotein (AFP). These markers have been 
shown to be o f value in evaluating pregnancies at risk for various anomalies and
aneuploidies.^ Second trimester maternal levels o f AFP, unconjugated estriol, 
and P-hCG are all at lower than normal levels in the presence o f  trisomy 18, with 
estriol being the most sensitive/ ^  ^  Triple marker serum screen testing has allowed 
earlier detection o f potential defects than routine sonographic screening alone; 
however, the triple screen test has also led to the identification o f  a population of 
patients that require genetic counseling and may require additional testing.
Ultrasound is the other non-invasive test used to detect chromosomal 
abnormalities. This method o f surveying the fetus allows for information to be 
obtained about the fetus and its environment.^ Specific anomalies can be viewed 
on ultrasound that correlate highly with trisomy 21 and trisomy 18. The 
incorporation of ultrasound as a prenatal screening tool may be related to 
improved perinatal and maternal outcome while avoiding the use o f invasive 
procedures.’
Amniocentesis is the “gold standard” test in that it provides the definitive 
diagnosis of chromosomal aberrations.W om en who screen positive on a triple 
test are typically offered chromosomal analysis with amniocentesis; however, this 
test is an invasive procedure involving needle aspiration o f amniotic fluid and 
cells." Amniocentesis is a procedure which is associated with complications for 
the mother and her unborn fetus. Although the risk of procedure-related 
pregnancy loss is small, it is important for women undergoing this invasive 
procedure to be informed o f such risks."
Trisomy 18 is a chromosomal abnormality that results in an extra 
chromosome 18, causing a condition that is eventually lethal. The second 
trimester incidence of trisomy 18 is approximately 1:2400 with a birth incidence 
of approximately 1:8000. The difference in the incidence rates is due to a 70% 
fetal loss in the third trimester.^ Even after successful delivery, the prognosis 
remains poor with at most a 10% survival rate up to one year.'^ This poor 
prognosis makes diagnosis o f  trisomy 18 important. Prenatal diagnosis would 
provide the patient with a variety o f options including termination o f the 
pregnancy, avoidance o f cesarean section, delivery locally with conservative 
management, or emotional preparation for the delivery o f an abnormal neonate.'^ 
Data suggests that ultrasound following a positive triple marker screen 
may provide guidance regarding the decision for definitive diagnosis with 
amniocentesis in trisomy 21. Very recent data suggests that this may also be 
possible for trisomy 18; however, studies published thus far concerning abnormal 
triple screen have indicated the need for further evaluation with ultrasound or 
ultrasound in combination with amniocentesis. This project will focus on the 
utilization o f non-invasive prenatal screening to guide the decision for 
amniocentesis for the purpose o f trisomy 18 detection.
Statement o f Problem 
Research involving the prenatal diagnosis o f trisomy 18, without the use 
of amniocentesis, has been mostly inconclusive. Research exists on the 
sonographic findings o f trisomy 18 and the parameters o f triple marker serum 
screen, but little research has been conducted on the risk o f  trisomy 18 based on
the combination o f these two antenatal tests. The combination o f ultrasound with 
the biochemical markers is thought to yield a more sensitive predictive risk o f 
fetal anomalies for women to base their prenatal decisions on.'^ Many women in 
institutions throughout West Michigan are currently being offered triple marker 
screening as part o f routine prenatal care. Women who are offered the option to 
undergo maternal serum screening would be counseled on the significance o f the 
results so that they are able to make informed decisions on further testing. Those 
women who screen positive for trisomy 18, which is defined as a risk greater than 
1:250, typically undergo further evaluation by ultrasonography. The question 
which arises is how to counsel women on the likelihood o f trisomy 18 based on 
ultrasound findings and abnormal triple screen. Specifically, does a normal 
ultrasound further reduce the risk o f trisomy 18 and possibly obviate the need for 
invasive testing by amniocentesis?
Purpose
The piupose of our study is to reduce invasive prenatal testing with its 
associated perinatal risks. Kellner et al. report a potential loss o f 3 to 4 unaffected 
fetuses out o f a  group of 700 patients as a result o f amniocentesis. '^  Older women 
who have delayed childbearing and those that have had previous treatment for 
infertility may not consider the risk of amniocentesis to be low enough to justify 
detecting the chromosomal abnormality.* We hope to reduce the amount of 
invasive testing by determining whether a normal ultrasound following an 
abnormal triple screen reduces the risk o f trisomy 18 to the point where 
amniocentesis would carry a greater risk than that o f the chromosomal
abnormality. This information will contribute to a step-wise approach in 
evaluating pregnant women that have screened positive for trisomy 18.
Significance o f the Problem
Prenatal diagnosis of chromosomal abnormalities is important in that it 
allows the practitioner to provide the patient with options. In this study, we are 
trying to determine the probability o f the fetus having trisomy 18 with less 
invasive and less risky procedures. Unfortunately, the majority o f genetic 
amniocenteses are performed on normal fetuses.'^ The average pregnancy loss due 
to genetic amniocentesis is roughly 1 in 270. Therefore, it is important to 
determine techniques that define a more select group o f candidates for invasive 
prenatal testing to decrease fetal losses due to amniocentesis.'^ By reducing 
invasive procedures, there is a decreased risk to the fetus as well as a reduction in 
unnecessary health care expenditure. Therefore, we hope to decrease the size of 
the population that will need further invasive testing for definitive diagnosis of 
trisomy 18. As health care providers, education is a vital component in delivering 
quality patient care. This research will contribute information for providers to use 
in counseling patients who have an abnormal triple screen.
Further research is needed in detecting trisomy 18 with triple marker 
screening and ultrasound. Yankowitz et al. conducted a recent study to evaluate 
the efficacy of prenatal serum screening for trisomy 18. The investigators 
concluded that combining serum screening with detailed ultrasound might further 
define the population that would most benefit fi-om invasive testing.^ We hope to 
extend the validity o f the study with this objective in mind by investigating a new
sample population in a different geographical area. We will evaluate a population 
of patients at an increased risk for trisomy 18 based on mid-second trimester triple 
serum screening and review the patients’ ultrasound findings. The expected 
outcome of this study is to determine how risk may be assessed on the basis of 
ultrasound findings.
CHAPTER TWO 
REVIEW OF LITERATURE
Trisomy 18
Trisomy 18 is the second most common autosomal trisomy with a birth 
incidence between 1:7000 and 1:8000.‘^ ‘* The low birth incidence o f trisomy 18 
is directly related to the increased number (70%) o f spontaneous abortions in the 
third trimester o f life.'* This relatively lethal condition is most often caused by a 
meiotic non-disjunction o f chromosome 18.” Similar to trisomy 21, the birth 
incidence of trisomy 18 increases with maternal age.'* Long term survival is rare 
in that approximately 50% o f trisomie 18 fetuses will die within 10 days to 2 
months of birth and over 90% by 100 days.^ '’ An infant with trisomy 18 will 
rarely survive beyond one year since this condition is associated with multiple 
structural abnormalities and extreme growth retardation.'® '* These structural 
malformations can be seen and detected on ultrasonography.
Trisomy 18 remained an unrecognized entity until 1960 when the first full 
report o f a child with trisomy 18 syndrome was described by Edwards, Hamden, 
Cameron, Crosse, and Wolff.^' At the same time, Patau, Smith, Therman, Inhorm, 
and Wagner reported the discovery o f two infants with a  similar syndrome; 
however, the researchers were only able to identify the extra chromosome as 
being from the E group which consists o f chromosome numbers 16 to 18. In an 
addendum, they mentioned 4 more cases and were able to identify the
chromosome as number 18.^ Subsequent reports o f similarly affected infants soon 
followed. Patau, Therman, Smith, and DeMars compared the abnormalities o f the 
two affected fetuses against the infant Edwards et al. had described and concluded 
that all o f these cases represented the same disorder caused by an extra 
chromosome number 18.^ The most prominent clinical abnormalities noted in 
these trisomy 18 infants were: mental retardation with moderate hypertonicity; 
low-set malformed ears; small mandible; flexion of the fingers with the index 
finger overlapping the third; and severe failure to thrive. The flexion o f the fingers 
with the index overlapping the third digit was significant for diagnosis o f the 
syndrome because it is such an imusual anomaly.^ The phenotypic expression of 
trisomy 18 was found to vary with a wide range o f anomalies. Each one, 
however, was not present in every patient.^
Another early study in 1962 reported on 6 definite cases and 1 possible 
case o f trisomy 18.^ These cases were confirmed by cytological preparation and 
analysis. The most fi*equent anomalies noted of these seven trisomy 18 cases 
were: apparent mental retardation; failure to thrive; flexion and deviation o f the 
fingers; low-set and malformed ears; micrognathia; defectively ossified and short 
sternum; diaphragmatic hernia or eventration; hypertonia; limited hip abduction; 
dorsiflexed and short great toe; malformation of the heart; malformation o f the 
kidney; prominent occiput; diastasis recti abdominus or peri-umbilical hernia; 
rocker-bottom feet or equinovarus; and limpness and hypotonia at birth.^ The 
investigators concluded that the trisomy 18 syndrome was a well-defined entity.^
While there are many published descriptions o f trisomy 18, there is little 
information about the cause o f death and the length o f survival. Embleton et al. 
explored the cause o f death because many clinicians blamed the rapid demise o f 
the trisomie fetus on congenital heart disease.^^ The researchers conducted a 
retrospective study for all cases of trisomy IS between 1986 and 1992. Of the 
282,583 births during that time, 66 fetuses at 18 weeks gestation with trisomy 18 
were identified. O f the 66 trisomie pregnancies, 23 were terminated, 6 
spontaneously aborted, 3 were stillborn, and 34 were bom living. The observed 
prevalence was 1 in 4274 at 18 weeks gestation. The prevalence decreases to 1 in 
8333 live births at the time o f delivery.*^ Trisomy 18 was diagnosed antenatally in 
28 cases. O f these 28 cases, only two were carried to term. The mode of delivery 
in 64% of the cases was by cesarean section. In this group, only one case had 
been diagnosed antenatally and cesarean section was performed to save the 
unaffected twin o f the trisomie baby. Thirteen o f these cesarean sections were 
performed due to fetal complications such as fetal distress and cord prolapse.
Prior diagnosis might have allowed for vaginal delivery. Twenty-one infants were 
determined to have cardiac malformations. Nine babies died within a few hours 
following birth. Only three cases were presumed to expire from cardiac 
abnormalities. None o f the infants who lived beyond two days died o f cardiac 
complications; therefore, cardiac surgery would not have affected fetal outcome. 
The most common mode o f death was found to be central apnea, and this was the 
cause o f death in 10 cases.^^
Prenatal Screening
Screening programs for pregnant women have caused much debate since 
the advent of tests such as amniocentesis and chorionic villus sampling. More 
specifically, there has been continued debate about which populations should 
undergo such testing because o f health care cost and the risks associated with 
them. Previously, prenatal screening was only offered to women over 35 because 
of the invasive nature o f  the tests. Without a non-invasive screening test, fetal 
loss due to testing and the cost of the procedure limited the efficacy o f  prenatal 
diagnosis. Use o f  such screening programs as ultrasound and triple marker 
screening have raised many questions about counseling and testing protocol.
Screening for chromosomal abnormalities has been traditionally offered to 
women considered to be at risk because of advanced age or other risk factors. 
Almost all women presently are offered some form o f prenatal screening which 
may include ultrasound, triple marker screen, and amniocentesis. The prenatal 
screening tools available to women during pregnancy have continued to improve 
and multiply throughout the past ten years.* With new technology and availability 
o f prenatal screening, some researchers have become concerned about the 
specificity and sensitivity o f  the tests. For example, Doman et al. expressed 
concern about the extension o f these tests into populations which have not been 
researched and whether this would result in increasing numbers o f false positive 
results and more unnecessary invasive testing. Doman et al. felt prenatal 
diagnosis through early screening would allow parents to make informed
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decisions. They foresaw a need for uniformity in the way the tests are offered and 
interpreted in order to decrease false positive results.^
Increased availability o f procedures to detect fetal abnormalities prenatally 
has caused some researchers to question the impact caused by the technology. A 
study done by Forrester et al. examined the effect o f prenatal diagnosis and 
elective termination on the prevalence of certain birth defects.^ They included 
electively terminated cases into calculations o f birth prevalence rates and found 
that this increased the rates by more than 50% for 5 o f the 10 birth defects studied. 
Elective terminations had the most effect on the rates o f neural tube defects 
(NTD) and chromosomal abnormalities. By taking into consideration the number 
o f elected terminations, there was a 58% increase in trisomy 13 rates and 100% 
increase in trisomy 18 rates.^ Birth defects such as anencephaly, trisomy 18, and 
trisomy 21 that result in a poor prognosis or substantial disability were more 
likely to end in elective terminations after prenatal diagnosis.
There is often controversy over the need to have a screening program for 
trisomy 18 due to its low birth prevalence and the high mortality rate for affected 
infants. Prenatal diagnosis o f trisomy 18 allows the parents to prepare themselves 
for the birth o f abnormal child with a poor chance for survival. On a psychosocial 
level this information can prove to be valuable to parents to allow for adequate 
grieving and decision making. Medical concerns such as a high rate o f cesarean 
section in association with trisomy 18, support the need for antenatal 
identification o f these infants as well. When trisomy 18 remains undiagnosed 
prenatally, there is a high rate o f  cesarean section in these mothers due to the
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frequent association between trisomy 18 and intrauterine growth retardation 
Diagnosis o f fetal distress is twice as common in infants with 
growth retardation. Cases in which primary cesarean section was performed for 
fetal distress resulted in an unjustified risk to the mother when ultimate fetal 
outcome is unfavorable either way.“
Triple Marker Screening 
As stated previously, invasive prenatal tests cannot be offered to every 
pregnant woman because of the cost o f such procedures and the associated 
complications. A number of non-invasive screening tests aimed at selecting 
higher risk pregnancies have been developed but are continuously in need o f 
improvement. Screening for chromosomal abnormalities includes serum marker 
screening, advanced maternal age, and ultrasound findings. The maternal triple 
marker serum screen is the most widely used prenatal screen for chromosomal 
abnormalities. This screen consists o f three biochemical markers: P-human 
chorionic gonadotropin (P-hCG); unconjugated estriol (uE3); and alpha 
fetoprotein (AFP). Each o f these biochemical markers is produced by the fetus or 
the placenta and passes into maternal circulation. Human chorionic gonadotropin 
is produced by the placenta and is a glycoprotein similar to luteinizing hormone 
(LH), follicle stimulating hormone (FSH), and thyroid stimulating hormone 
(TSH). The hCG consists o f an alpha-subunit and a beta-subunit. The levels o f 
P-hCG follow a specific pattern throughout the gestation o f a fetus. This pattern 
begins with implantation to 8 weeks gestation when the levels begin rise. The
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concentration plateaus from 8 to 12 weeks gestation, decreases from 12 to 18 
weeks, and plateaus again until term.~^ Unconjugated estriol is formed from 
dehydroepiandosterone sulfate (DHEAS) which is converted in the fetal liver to 
16-alpha-OH-DHEAS and then becomes unconjugated estriol in the placenta.
AFP is produced primarily in the fetal liver as well as the yolk sac and the 
gastrointestinal t r a c t . F e t a l  plasma levels o f AFP peak between 10 and 13 
weeks and then decrease until term.”
Maternal serum screening is a  blood test that is typically offered between 
16 and 21 weeks gestation. The biochemical markers are calculated and reported 
in Multiples o f the Median (MoM). These serum markers are initially measured 
in mass units and then converted to MoMs based upon proven normal pregnancies 
at the same gestational age. By reporting the values in this way, the values can 
be adjusted for biological variables that are known to affect the maternal serum 
levels such as maternal weight, insulin-dependent diabetes, and race.^*’^ ° In 
screening specifically for trisomy 18, the levels for all three biochemical markers 
are lower than normal values for gestation age.
Merkatz et al. were the first to observe a decreased maternal biochemical 
marker in a trisomie 18 fetus.”  Their research was prompted by an index case o f 
“undetectable” maternal serum AFP in a 28 year-old primigravid women at 16 
weeks that resulted in the birth o f a trisomy 18 infant. During the pregnancy the 
mother had inquired about amniocentesis but was told the procedure was not 
recommended due to her young age; however, she did undergo routine AFP 
screening and had two results that were described as “below sensitivity” o f the
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test. At the time, the literature revealed that the significance o f low midtrimester 
maternal AFP levels was unclear but seemed to be correlated with higher than 
estimated rates o f spontaneous abortion. This observation incited Merkatz et al. 
to further research this relationship.”
Merkatz et al. used three different populations in a retrospective study of 
prenatally diagnosed chromosomal abnormalities.”  The first group was evaluated 
for maternal age distribution. The researchers found that among all trisomy 18 
and trisomy 21 births, 68% occurred in women who were 34 years o f age or 
younger. Due to the fact that almost three-fourths o f  trisomie affected births 
occur in women who are younger than the standard cutoff o f age 35 and due to the 
expense of prenatal diagnosis, Merkatz et al. suggested the need for a screening 
tool to identify a high-risk subset of pregnant women. The second and third 
populations evaluated the use of AFP as a screening tool. They concluded that 
using low AFP values as a criterion to do further prenatal testing for diagnosis 
would reduce the number o f  amniocenteses to approximately one chromosomal 
abnormalities for every 35 to 40 performed. This ratio is compared to 1 to 2 
chromosomal abnormalities for every 100 amniocenteses performed when 
maternal age is used as the criterion.”
The earliest screens measuring biochemical analytes were first performed 
using AFP exclusively to screen for Down’s syndrome. With continuing research, 
p-hCG and uE3 were used in addition to AFP because o f an increased detection 
rate of aneuploidy. Kellner et al. found using all three markers together in
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correlation with maternal age increased the detection rate o f chromosomal 
abnormalities versus AFP and hCG without estriol.'^ The results of the study also 
indicate a higher detection rate by using the three serum markers with other 
chromosomal abnormalities without a change in the false positive rate.''*
With progression in research on the accuracy o f the triple marker 
screening test for detecting chromosomal abnormalities, Kellner et al. raised the 
question whether amniocentesis needs to be offered to a more defined 
population.'■* Using the triple screen in women age 35 and greater in the study 
group, a total o f 700 women were spared from undergoing amniocentesis, while 4 
out o f 5 cases of trisomy 21 were detected by offering amniocentesis to only 186 
women. Statistically, the loss of 3 to 4 unaffected fetuses would be spared as 
well. On the other hand, offering amniocentesis to women less than 35 years of 
age resulted in an increase detection of abnormalities. The researchers also noted 
that the ultrasound was able to detect an additional 2 cases o f trisomy 21 and 
suggested that it may be a useful additional screening tool. In conclusion, the 
researchers found the triple screen in correlation with maternal age has increased 
detection o f chromosomal abnormalities, allowing for another option for older 
women who are usually candidates for amniocentesis.
Maternal serum screening for trisomy 18 was initiated as an extension of 
second-trimester maternal blood screening for Down’s syndrome. In 1992 
Kellner et al. began screening for trisomy 18 in addition to their trisomy 21 
screening study. The study population included 8,649 women o f the original 
10,605 who were initially screened for trisomy 21. A test was considered screen
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positive for trisomy 18 if the three biochemical markers were low. The screen 
positive test was determined with the following values: AFP < 0.75 MoM, uE3 < 
0.60 MoM, and p-hCG < 0.55 MoM. Of the 8649 serum samples tested, 23 
women screened positive for trisomy 18. Twenty of these women elected to 
undergo amniocentesis. Two cases were detected by amniocentesis resulting in 1 
case per 11.5 amniocenteses. There was 1 case that was missed by the screening 
and one fetal death in which trisomy 18 could not be ruled out."
Leporrier et al. examined 33 cases o f  known trisomy 18 pregnancies in 
order to evaluate two maternal serum biochemical markers, specifically 
unconjugated estriol and human chorionic gonadotropin.'^ The levels for both u£3 
and hCG were found to be significantly lower as compared to unaffected 
pregnancies. The researchers point out the advantages to using these biochemical 
markers as routine screening are a reduction in the number o f amniocenteses 
performed, as well as earlier detection of the disease.'^
With continuing research on the detection o f trisomy 18, the triple serum 
screen was found to be a better screen than AFP alone or AFP and P-hCG in 
combination. With the addition o f estriol, 60% o f pregnancies with trisomy 18 
would be detected at the same false positive rate o f 0.2%. The detection rate 
doubles in comparison to using only AFP and P-hCG.^ In 1993, Barkai et al. 
concurred with previous studies that the triple marker screen could be modified to 
detect trisomy 18 as well as trisomy 2 1 The difference between the two 
syndromes is a  decreased level o f P-hCG in trisomy 18 in contrast with an
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increased level in trisomy 21. Depending on the risk cut-off rate o f either 1:10 or 
1:1 GO, multiple marker screening could potentially detect 67-80% of trisomy 18 
cases, with a false positive rate o f 0.3-0 6% respectively
As prenatal screening programs routinely began using the triple marker 
screen for the detection of trisomy 18, research was directed towards evaluating 
the efficacy o f the triple marker screen. A prospective intervention trial to 
evaluate the performance o f a screening protocol for trisomy 18 in routine practice 
was carried out by Palomaki et al. in 1991.^' A total o f 92 of the 19,491 singleton 
pregnancies studied were identified as high risk, meaning they were screen 
positive for trisomy 18. The following serum biochemical marker levels were 
defined as a positive screen or high risk pregnancy: AFP < 0.75 MoM, uE3 <
0.60 MoM, and hCG < 0.55 MoM. Ninety-six percent o f the women elected 
further karyotyping by amniocentesis. Six o f the 92 screen positive women 
actually had fetuses with trisomy 18, making the odds o f having an affected fetus 
1:14. The results indicate an estimated detection rate o f 85% using this screening 
protocol. Thus, the method utilizing the three serum markers compared to the 
alternative method of using p-hCG alone as a screening tool shows an improved 
detection rate and a decreased false positive rate.^'
A study by Yankowitz et al. was done to determine the efficacy o f  the 
prenatal serum screen for trisomy 18.*^  Maternal serum samples were drawn 
between 15 and 20 weeks gestation. Those screens considered positive for 
trisomy 18 had maternal serum AFP < 0.75 MOM, estriol < 0.60 MOM, and p-
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hCG < 0.55 MOM. Serum AFP values were corrected for maternal weight, race, 
and Type 1 diabetes mellitus. Estriol and p~hCG were corrected for maternal 
weight. Fetal ultrasound evaluation included biometric parameters, assessment of 
fetal structure, and amniotic fluid. Patient follow-up was obtained through 
evaluation o f karyotype if amniocentesis was performed, birth certificate data, or 
telephone contact with the patient or physician. During the study 40,762 women 
were screened with 175 being screen positive for trisomy 18. The results 
indicated that eight fetuses out of the 175 that had a positive triple screen were 
actually diagnosed with trisomy 18. One hundred twenty-one women o f the 175 
that had a  positive screen elected to undergo amniocentesis, which resulted in the 
identification o f  only one trisomie 18 fetus. O f the 8 fetuses who were afflicted 
with trisomy 18, only 3 mothers elected to undergo ultrasound after having 
screened positive for the triple marker serum screen. Remarkably, all three of the 
fetuses showed abnormalities on ultrasound.^
Yankowitz et al. argued that combining serum screening with genetic 
ultrasound may improve the predictive value o f those who screen positive for 
trisomy 18. This would be accomplished by targeting a more precise group at a 
higher risk o f  trisomy 18 for amniocentesis. By combining ultrasound with the 
triple marker screen, the researchers theorized that the number of women 
undergoing amniocentesis could have been reduced from 121 to 27. Yankowitz et 
al. go on to suggest that all women who screen positive should first undergo 
ultrasound and then be counseled for further genetic testing based on the
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calculated risk o f trisomy 18. Normal ultrasound results would potentially 
eliminate 80% o f the risk of trisomy 18 *
Ultrasonographic Findings 
Ultrasound is a diagnostic tool that is used by physicians to assist them in 
detection of multiple gestations and fetal abnormalities. In women with 
unreliable dates o f last menses, an estimation of gestational age can also be 
determined through the use of ultrasound. Real time ultrasound using high 
frequency sound waves to produce a two-dimensional image gives the physician 
the capability to survey both structural and functional characteristics o f the fetus, 
as well as the location and morphology of the placenta. A study performed by 
Magriples et al. evaluated the accuracy o f routine ultrasound screening for fetal 
anatomy and anomalies.^^ The investigators found routine ultrasound screening to 
be extremely sensitive in the detection o f fetal anomalies in women screened 
before 26 weeks gestation. Sensitivity and specificity o f ultrasound screening in 
this study were found to be 71.4% and 99.4% respectively.^^ Findings are 
significant due to the fact that a majority o f fetal malformations occur in pregnant 
women having no known risk factors.
Ultrasound has made it possible to visualize structural malformations 
associated with chromosomal abnormalities and neural tube defects. There has 
been ongoing research on the use o f ultrasound as a routine prenatal screening for 
specific chromosomal abnormalities such as Down’s syndrome and trisomy 18. 
The motivation to incorporate ultrasound as a routine prenatal screening is to 
improve perinatal and maternal outcome while decreasing the use o f invasive
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testing. Recent research has been able to describe sonographically detectable 
abnormalities associated with specific chromosomal anomalies.
Benacerraf et al. conducted a series o f studies focusing on the accuracy 
and limitations o f ultrasound in the detection of trisomy 18. This resulted in their 
development o f a  scoring system for sonograpic features. In one o f their early 
studies, Benacerraf et al. examined the accuracy and limitations o f prenatal 
ultrasound in identifying fetuses with trisomies 13 and 18.^  ^Patients scanned 
between January 1, 1984 and February 1, 1987 who had cytogentic diagnoses of 
trisomy 13 or 18 were included in the study. All ultrasounds were done between 
15 and 40 weeks gestation without any knowledge o f karyotype. There were 15 
cases o f trisomy 18. Twelve of the 15 cases had abnormalities detected by 
ultrasound. Eleven o f these fetuses had abnormalities o f  the hands or feet, three 
had diaphragmatic hernia, and one had micrognathia. O f the twelve cases with 
abnormalities detected by ultrasound, six were scanned between 15 and 22 weeks, 
one at 25 weeks and 5 between 31 and 40 weeks. All three fetuses who did not 
have sonographic abnormalities were seen between 16 and 17 weeks.
Sonographic identification for trisomy 18 in this study was approximately 80%." 
With this study Benacerraf et al. were unable to conclude whether ultrasoimd is 
predictive in diagnosing trisomies due to the small number o f cases.
In a following study, Benacerref et al. further examined abnormalities seen 
on ultrasound and derived a scoring system to be used to detect fetuses at 
increased risk for aneuploidy." The system was scored as follows; nuchal fold 2, 
major defect 2, short femur 1, short humerus 1, and pyelectasis 1. A score o f 2
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would mean increased risk o f anueploidy. Using this system there is a potential 
for identifying as many as 80% o f trisomy 21 fetuses, 100% of trisomy 13 and 18 
fetuses while keeping a low false-positive rate o f  4.4%.^
In a 1994 follow-up study, Benacerref et al. evaluated the ability to 
determine autosomal trisomy fetuses by using their previously determined scoring 
system for sonographic features.^^ They selected a new population that was 
scanned before karyotyping to avoid overlap with their earlier study. The two 
new criteria added to the scoring system were hyperechoic bowel = 1 and choroid 
plexus cysts = 1. The amniocentesis findings identified 60 trisomie fetuses with 
13 trisomy 18 fetuses. These were compared to 106 control fetuses that 
underwent scanning and amniocentesis at approximately the same time. A score 
o f two was used as an indication of increased risk o f anueploidy warranting 
karotyping. This score of 2 identified 11 o f the 13 trisomy 18 fetuses or 85%.
The 2 fetuses with trisomy 18 that were not identified were scanned at 15 weeks 
or earlier which limits the structural survey. According to Benacerraf et al., the 
optimal time to perform sonographic evaluation is 18 weeks since the fetal heart 
can be evaluated better. If only fetuses that were scanned at 18 weeks or older 
were included then 11 of 11 or 100% o f trisomy 18 fetuses would have been 
detected. Benacerraf et al. suggest that the scoring system with triple marker 
screening may allow for a refined prediction o f risk o f aneuploidy and thereby 
performing fewer amniocentesis that have a higher sensitivity and positive 
predictive value in detecting aneuploidy
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A case review o f the ultrasonographic findings in 47 fetuses with trisomy 
18 was carried out by Nyberg et al. in 1992.^* Twenty-nine o f the 47 total fetuses 
were examined between 14 and 24 weeks. The other 18 fetuses were scanned 
after 24 weeks. Abnormalities excluding choroid plexus cysts were identified in 
83% of the fetuses. The abnormalities detected in this study included the 
following: intrauterine growth retardation (51%); cardiac defects (38%); cystic 
hygromas, lymphedema or nuchal thickening (19%); prominent or enlarged 
cistema magna (19%); meningomyelocele (17%); omphalocele (21%); renal 
abnormalities (15%); single umbilical artery (13%); clubbed or rocker bottom feet 
(21%); and clenched hands (19%).^^ Cardiac defects, enlarged cistema magna, and 
lUGR were more likely to be detected in the third trimester in contrast with cystic 
hygromas. Clubbed feet or persistently clenched hands were the most common 
abnormalities o f  the extremities.^^ This study demonstrates the use o f ultrasound 
in detecting trisomy 18 in reporting ultrasonographic abnormalities associated 
with the syndrome. This further points to the efficacy o f using ultrasound to 
evaluate patients with an increased risk for trisomy 18 based on serum 
biochemical markers.
While previous studies have reported an 80 to 85% ability to detect 
abnormalities specific to trisomy 18, the ultrasoimds have inconsistently been 
performed at various gestational ages between 12 and 40 weeks.^^ Most pregnant 
women undergo a screening ultrasonogram early in the second trimester. A study 
by Shields et al. focused on the prenatal detection o f ultrasonographic 
abnormalities in fetuses with trisomy 18 during the early second trimester.^’ Their
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patient population included all patients that were referred to the University of 
Washington Prenatal Diagnosis Center between January 1, 1987 to June 30,1996. 
The fetuses o f these women were between 14 and 22 weeks gestation with a fetal 
karotype indicating trisomy 18. Thirty-five cases o f trisomy 18 were identified. 
The mean time o f evaluation for the fetuses was 17.2 ±  2.0 weeks. The ultrasound 
evaluation included standard biometry measurements of biparietal diameter, head 
circumference, abdominal circumference, and femur length as well as fetal 
anatomic evaluation o f the cerebral ventricles, posterior fossa, spine, four- 
chamber view of the heart, stomach, kidneys, and bladder. O f the 35 fetuses 
studied, 30 (86%) had at least one sonographic abnormality detected. The most 
common abnormality detected was persistent abnormal positioning o f fetal fingers 
or a clenched fist. Abnormalities in regard to fetal hands were found in 18 cases 
with 16 having positional abnormalities o f the fingers. Abnormal positioning of 
the hand was seen in almost 90% o f the fetuses whose hands were evaluated. 
Shields et al. comment that while careful documentation o f hands would not 
identify all abnormal fetuses, it would take little additional time to obtain during a 
routine scan. This finding seems to have a high predictive value in detecting 
chromosomally abnormal fetuses. O f the 5 fetuses that had anatomically normal 
ultrasounds, there was only one case in which the hands were noted to be 
sonographically normal. The next most common finding was choroid plexus cyst. 
Fifteen patients or 43% were noted to have this abnormality. In 5 of these 15 
cases, a choroid plexus cyst was the only abnormality noted. Other anomalies 
found included: abnormal cranial shape such as the lemon-shaped and the classic
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strawberry-shaped heads; two-vessel umbilical cord; cardiac defects; intrauterine 
growth restriction; omphalocele; neural tube defects; and cystic hygroma or 
lymphangiectasia. This study notes that a majority o f fetuses with trisomy 18 will 
have ultrasonographic abnormalities that can be detected between 14 and 22 
weeks during the screening ultrasonographic examination.^^
In a previous study by Shields, 274 fetuses had isolated choroid plexus 
cysts on ultrasound with only 7 fetuses having abnormal karotypes.^* The risk o f  
trisomy 18 in fetuses with an isolated choroid cyst noted on second trimester 
ultrasound was determined to be 1.9%. At this time. Shields at el. suggested that 
an isolated choroid cyst in a fetus with a normal maternal serum screen may not 
need invasive testing.^*
Vintzileos et al. and Bahado-Singh et al. both conducted studies that 
focused on determining the importance o f ultrasound and triple marker screen 
used in combination to detect trisomy 21 risk. Bahado-Singh et al. used 
ultrasonographic biometry and anatomic survey to obtain the best combination o f 
biometry parameters for the detection o f  Down's syndrome and other 
chromosomal anomalies.^^ This study established values for nuchal thickness, 
humerus length, femur length, and fetal anatomy which would elicit a statistically 
significant percentage o f chromosome abnormality in a positive triple screen 
population. With the use o f a combination of ultrasonographic parameters in the 
present study, fetuses at greatest risk for trisomy 21 and other significant 
chromosomal abnormalities such as trisomy 18 among positive triple screen 
pregnancies were identified. The researchers thus concluded that a normal
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ultrasonography result significantly reduces the risk of any clinically significant 
chromosomal defect/^ A previous study by Bahado-Singh et al. showed that the 
chance o f  finding Down’s syndrome in a  triple-screen-positive pregnancy is 
significantly reduced with a normal nuchal thickness and no fetal structural 
abnormalities on ultrasonography.’ They also established that the risk from 
amniocentesis significantly exceeds the risk o f finding Down syndrome in these 
same fetuses with normal nuchal thickness and no fetal structural abnormalities. 
Thus, a major benefit o f defining those triple-screen-positive pregnancies at low 
risk for chromosomal abnormalities as noted in the present study is a  potential 
reduction o f performing genetic amniocentesis on such a population.’
In response to conflicting results o f prenatal ultrasonographic findings in 
trisomy 21, Vintzileos et al. conducted a study to establish the average sensitivity 
and specificity o f  ultrasonographic markers in the second trimester of pregnancy.'^ 
Based on these findings, the researchers were able to derive an adjusted risk for 
trisomy 21 for both high- and low-risk populations.'^ The significance of this data 
is that second-trimester ultrasonography is an important key in adjusting the need 
for genetic amniocentesis in women with abnormal triple serum biochemistry 
results. These results allow for better selection o f candidates for genetic 
amniocentesis and thus minimize amniocentesis-related fetal loss. Both studies 
by Vintzileos et al. and Bahoado-Singh et al. validate the significance of 
ultrasonographic biometry in combination with a positive triple serum screen in 
detecting trisomy 21 prenatally.
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Amniocentesis
Amniocentesis was first known to be performed for genetic studies in the 
1950’s; however, the first report that a fetal karyotype could be obtained from 
cultured amniocytes for the purpose o f prenatal diagnosis was made by Steel and 
Breg in 1966."^^' Then, in 1972, Hsu et al. reported one o f the first cases of 
trisomy 18 diagnosed prenatally with the use of transabdominal amniocentesis.*’ 
This procedure was performed at 16.5 weeks gestation on a 40 year old women 
secondary to her advanced maternal age. Chromosomal analysis, performed on 
the amniotic fluid culture, indicated trisomy 18. Using prenatal amniocentesis and 
pathologic examination, the researchers were able to conclude that trisomy 18 
could be detected as early as twenty weeks gestation.”
With the heightened use o f amniocentesis, safety, as well as its effects on 
the fetus and maternal outcome, was under debate. In 1971, the National Institute 
of Child Health and Human Development (NICHD) initiated the National 
Registry for Amniocentesis to conduct a prospective study to investigate the 
safety and accuracy o f mid-trimester amniocentesis.^* The study involved 1,040 
subjects and 982 controls. The registry data focused on immediate complications 
of amniocentesis such as fetal loss at the time of delivery, birth difficulties, 
congenital abnormalities, and follow-up at one year o f age in order to note any 
possible developmental problems. The overall fetal loss by the women undergoing 
amniocentesis was 3.5% compared to 3.2% for the controls. There were no 
significant findings for the infants in death rates, medical history, or physical 
growth between the two groups at the one-year follow-up. Overall, the NICHD
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study group concluded that amniocentesis was a safe procedure; however, they 
did not discount the potential risks that accompany the procedure even though the 
data indicated the actual occurrence o f  these risks to be small. The researchers 
felt the results o f the study should help to advocate for the use o f amniocentesis in 
older women with an increased risk for Down’s syndrome.^^
Since the time o f the report by the NICHD, several studies have followed 
and have shown a small but significant procedure-related loss associated with 
amniocentesis.^^"^ According to the bulletin constructed by the AGOG study 
group on the safety and efficacy o f  amniocentesis, the risk o f fetal loss associated 
with amniocentesis was quoted as 1:200 procedures."*’ The procedure involves the 
introduction o f an ultrasound guided 20- to 22-guage spinal needle through the 
abdominal wall. The needle is then passed through the uterus and into the 
amniotic sac. Approximately 20 to 30 ml of amniotic fluid is extracted. The fluid 
contains amniotic cells which are then cultured and karyotyped." Amniocentesis 
is considered the gold standard for invasive prenatal diagnostic procedures; 
however, it is essential that patients be informed o f the possible risks o f 
amniocentesis including a procedural related loss o f 0.5 to 1.0%.*° "^^
Second trimester amniocentesis is currently offered on a routine basis to 
women at risk for Down’s syndrome and other fetal a n e u p l o i d i e s . ^ T h e  
population o f women at increased risk for fetal aneuploidies includes all women 
age 35 years and older since the risk o f  having a fetus with an autosomal trisomy 
increases significantly after this age.'^^ Other indications for prenatal diagnosis 
by amniocentesis include a positive maternal serum screen, history o f a child with
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a chromosomal abnormality, family history o f neural tube defects, and abnormal 
results on fetal ultrasonography/^ Although less than 25% of trisomy 21 infants 
are bom to mothers over the age 35, the risk o f having an affected fetus in the 
second trimester increases to 1 in 200.'^^* The risk o f  procedure-related fetal loss 
in this age group is considered to be the same or less than the risk of having a 
child with trisomy 21/° Because the birth incidence of trisomy 18 is much lower 
than that o f trisomy 21, the risk o f fetal loss secondary to amniocentesis may 
actually be higher than the risk o f having a trisomy 18 infant.
The study by Spencer and colleagues demonstrates the need for further 
research on performing routine amniocenteses on pregnant women who screen 
positive for trisomy 18.‘* In this particular study, the birth incidence of trisomy 21 
was found to be 12.6/10,000 as compared to an incidence o f 1.3/10,000 for 
trisomy 18. With the use o f maternal serum AFP and P-hCG for the prenatal 
diagnosis o f trisomy 18 and trisomy 21, a detection rate o f 50% with a false 
positive rate o f  1% and a detection rate o f 70% with a false positive rate of 5% 
were obtained, respectively. Therefore, 8.8 cases o f trisomy 21 would be detected 
for every 500 amniocenteses performed giving one case per 57 amniocenteses; 
however, the detection rate for trisomy 18 would result in 154 women undergoing 
amniocentesis to detect one case of trisomy 18. This is significant in that this 
would result in a loss of just as many normal fetuses as abnormal fetuses detected. 
Thus, it was concluded that the risk caused by follow-up amniocentesis was too 
great for the number of trisomy 18 fetuses detected at that time.'*
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Routine second-trimester amniocentesis for women at an increased risk o f 
trisomy 18 has not been found justifiable from a cost/benefit standpoint either. 
This aspect o f routine amniocentesis was explored in a 1998 study by Vintileos et 
al.^  ^The researchers performed a cost/benefit analysis and cost effectiveness 
determination o f three prenatal strategies for the detection o f trisomy 18. The 
strategy of universal amniocentesis for all women at an increased risk of trisomy 
18 was found to be much more costly than the strategy o f  no prenatal diagnostic 
work-up o f at-risk patients, and the strategy of genetic amniocentesis reserved for 
at-risk patients with abnormal ultrasound results. The universal amniocentesis 
approach would generate an annual cost o f approximately $12 million dollars and 
40 fetal losses whereas the targeted genetic ultrasound approach would cost only 
$5 million dollars annually with a fetal loss o f 8 as the result o f amniocentesis.^^ 
This study demonstrates that from a economic standpoint universal amniocentesis 
is not a cost effective option for mothers at an increased risk for trisomy 18.
Summarv
The research and development o f screening programs are focused on 
reducing the number o f women undergoing invasive procedures for definitive 
diagnosis o f chromosomal abnormalities. Performing amniocenteses on all 
women who screen positive on triple marker serum screen for chromosomal 
abnormalities is both costly and carries the risk for fetal loss. This lends support 
to further define a population at higher risk o f trisomy 18 in order to reduce the 
number of amniocenteses performed. When the risk o f the test is greater than the
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risk of the abnormality, the patient needs guidelines to make informed decisions 
regarding further evaluation.
Several studies have indicated the efficacy of triple serum marker screen in 
identifying trisomy 18.*’^ ' Many studies have also described abnormalities 
associated with trisomy 18.‘‘'^  Furthermore, studies have demonstrated the ability 
of these abnormalities to be detected on ultrasound.^^^* While there were a few 
ultrasounds that had no visible abnormalities but resulted in fetuses with trisomy 
18, most o f those ultrasounds were performed before 17 weeks gestation.^^^^ Most 
research published thus far has centered on altering the risk o f having a fetus 
affected with trisomy 21 using non-invasive methods. These studies demonstrate 
the significance of using ultrasound and triple marker screen in combination to 
determine trisomy 21 risk.'*'^’ The parameters and framework from these studies 
can be extended to research involving trisomy 18. More specifically, the use of 
ultrasound and triple screen in combination to identify a population at higher risk 
for trisomy 18 must be researched.
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CHAPTER THREE 
METHODOLOGY
Study Design
This study examined the risk o f trisomy 18 based upon triple marker 
serum screen results and ultrasound findings. The project was a correlational 
study of the relationship between an abnormal triple marker screen, a normal 
ultrasound, and the risk o f trisomy 18. A non-experimental design, specifically, a 
non-concurrent cohort study, was conducted to obtain data. This was 
accomplished through a retrospective and prospective chart review o f a cohort of 
pregnant women who had screened positive for trisomy 18. The retrospective 
aspect was conducted between June 1, 1996 through July 31, 1998. The 
remaining cases were followed from August 1, 1998 imtil September 30, 1999. 
The starting date for the study was chosen because June 1996 was when trisomy 
18 risk was first reported to the physician population. September 1999 was 
chosen as a cut off date in order to allow adequate time to obtain pediatric 
outcome prior to presentation o f  this project in March o f 2000. The advantage of 
using this particular study design was that it permitted a large population to be 
studied within a specified amoimt o f time. Also, due to the low incidence o f 
trisomy 18, access to the largest population possible was needed to obtain a 
sufficient number o f trisomy 18 cases. The use o f a retrospective design does
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have the possibility o f  missing data, loss to follow-up, and lack of uniformity in 
the recorded information.
The focus of the study centered around the results o f the triple marker 
screen and ultrasound as well as the outcome in terms o f presence or absence of 
trisomy 18. The triple marker serum screen results and ultrasound findings 
constitute the independent variables. The triple marker screen consists o f testing 
serum levels of AFP, P-hCG, and unconjugated estriol. In a positive test for 
trisomy 18, all of the serum levels are lower than normal in the second trimester.® 
Ultrasound was the other screening tool used to detect the presence o f trisomy 18. 
Research has shown that there are specific abnormalities seen on ultrasoimd 
commonly associated with trisomy 18. These sonographic findings include: 
intrauterine growth retardation; congenital heart disease; single umbilical artery; 
cystic hygromas; choroid plexus cysts; omphalocele; clenched hands; rocker 
bottom feet; meningomyelocele; renal anomaly; and enlarged cistema magna.^®^  ^
The dependent variable in the study was the presence or absence o f trisomy 18.
Studv Site and Subiects 
Study Site
The central site o f the study was conducted through Spectrum Health 
Downtown campus in conjimction with West Michigan Perinatology and 
Spectrum Health Downtown Genetic and Cytogenetic departments. These 
facilities serve the population o f West Michigan along with surrounding areas.
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The demographic profile o f this population ranges from urban to rural 
encompassing various ethnic and socioeconomic backgrounds.
Subjects
Subjects were initially recruited by referral through their primary 
physician for a triple marker serum screen based on their gestational age. All 
pregnant women with fetuses between the gestational age of 15 to 22 weeks are 
offered the triple marker serum screen. The study population included women 
who were screened through Spectrum Health Downtown Campus Genetic 
Screening Program. The cut-off levels at Spectrum Health Genetics lab for the 
biochemical analytes in the serum marker screen consist of the following: AFP 
0.70 MoM, estriol 0.55 MoM, and P-hCG 0.50. Using these levels, there is a 50% 
detection rate with a 2% false positive rate. Based on the levels o f P-hCG, AFP, 
and estriol, a risk for trisomy 18 was generated. The study sample included all 
women with a  calculated serum screen risk of greater than 1:250 for trisomy 18. 
These women then underwent ultrasound or ultrasound in combination with 
amniocentesis. A computer-generated list o f all positive results for trisomy 18 
was compiled. The risk calculation for trisomy 18 was instituted June 1, 1996. 
The women included in this study had screened positive between this date and 
September 30, 1999. Prior to June 1, 1996, the triple marker screen was being 
done but was not evaluated for trisomy 18 risk calculation. Excluded from the 
study were those with a normal risk based on recalculation with change in
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estimated date o f confinement (EDC), fetal demise at less than 20 weeks, and 
termination at less than 20 weeks without amniocentesis.
Equipment and Instruments 
This study was a chart review in which data were collected concerning 
ultrasound findings and fetal outcome. No direct instrumentation was used during 
the study. Ultrasoimd and amniocentesis were done prior to the chart review.
The technique o f ultrasound is widely used as a general, non-invasive 
screening tool and it is considered to be a safe method for obtaining information 
about the fetus and its environment/ Ultrasound biometry is now the gold 
standard for assessing fetal growth. A number o f second-trimester ultrasound 
findings have been found to be frequently associated with fetal aneuploidy 
including; smaller biparietal diameter; shorter femur length and humerus length; 
thickened nuchal fold; pyelectasis; increased bowel echogenicity; abnormal heart 
anatomy and abnormal flexion of the hands.^^ In trisomy 18, the most common 
structural abnormalities present on ultrasound consist of: cardiac or abdominal 
wall defects; central nervous system abnormalities; renal abnormalities; single 
umbilical artery; structural anomalies o f the hands and feet; and intrauterine 
growth retardation.^*'*’ The specificity and sensitivity of the ultrasound depends 
on a number o f factors including the quality o f screening equipment, the expertise 
of the ultrasonographer, and the specific abnormality being evaluated.
Amniocentesis for prenatal diagnosis is the most common invasive 
procedure offered to pregnant women who have an increased risk o f  chromosomal 
aberration."* The procedure involves the introduction of an ultrasound- guided
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needle through the uterus into the amniotic sac. A small amount of amniotic fluid 
is aspirated with the needle and then sent to a lab for genetic evaluation and 
karyotyping.^’
Validity and Reliability o f Amniocentesis
In 1976, the diagnostic accuracy of mid-trimester amniocentesis was found 
to be 99.4% by the NICHD National Registry for Amniocentesis Study Group 
(NICHD). Since the early 1970’s, the accuracy and reliability o f amniocentesis 
has been well established and is considered the “gold standard" for the diagnosis 
of chromosomal abnormalities.'® "
Procedure
The data was primarily collected through chart review o f those women 
who screened positive for trisomy 18 using triple marker screen through Spectrum 
Health Downtown Campus Genetic Screening Program. A list o f the women with 
abnormal triple screens was generated. The data needed for the study were 
retrieved from individual patient charts. A majority o f  the charts were available 
from the West Michigan Perinatology Office. The remaining charts were 
obtained through mailings and telephone calls to the woman’s primary care 
provider at the time o f pregnancy. Review consisted o f  maternal demographic 
data, triple screen results, ultrasound evaluation, amniocentesis rates and results, 
and outcome assessment based on amniocentesis results, office documentation, 
review o f birth records, or telephone contact with mother.
The data was collected by the three authors o f  the study, all o f whom are 
physician assistant students, and also Dr. Dawn De Witt. All data collectors were
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consistent in finding and recording the information from the individual charts. In 
cases in which charts could not be reviewed directly, a standard form was sent to 
the practitioners office requesting the specific information needed. Upon 
receiving the completed form, the information was transcribed in a manner 
consistent with the data directly obtained. Data collection began September 1998 
and continued through November 1999.
Because o f the design o f the study, there exist missing data and incomplete 
data. An exhaustive search for data was performed and all attempts to locate 
missing data was carried out. For charts outside o f the West Michigan 
Perinatology office, a  mailing was sent requesting information from practitioners 
on subjects in the study. Follow-up phone calls were made to those offices which 
had not responded to the initial request by mail. Attempts to further complete 
pediatric follow-up was carried out through phone calls to the mother and review 
of Spectrum Health’s labor and delivery log book.
There were no direct risks to the individual patients since this study was a
chart review. Maintaining patient confidentiality was the only concern for this
type o f study. Confidentiality was preserved by sequential assignment of
numbers to all patients so that names and identifying information were protected.
Throughout the study, patients were only identified and referred to by their
assigned number. Individual informed consent was not necessary due to
preserved confidentiality and absence o f direct patient contact.
T h is  s tu d y  w a s  d o n e  in  c o n j u n c t i o n  w i th  D a w n  D e  W itt. M D , c h i e f  O b s te t r ic s  a n d  
G y n e c o lo g y  r e s id e n t .
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CHAPTER FOUR 
RESULTS/DATA ANALYSIS
Study Population
A total o f 13,618 maternal subjects were screened for fetal trisomy 18 
from June 1996 to September 1999. O f the total number screened, 158 (1.2%) 
had a positive result. Ten were excluded from the study due to fetal demise or 
termination at less than 20 weeks gestation. Another 8 were excluded with 
recalculation of estimated date of confinement (EDC) and 1 subject was removed 
due to her non-pregnant status. Ultrasoimd data was not available on 19 o f the 
139 identified making the total number in our study population 120 (86.3%).
Techniques o f Data Analysis 
The study population was divided into two groups: normal ultrasound and 
abnormal ultrasound. The two groups were compared demographically to initially 
rule out any biases since the study was non-randomized. A comparison analysis 
of the collected data was performed using Pearson Chi-Square, Mann Whitney U, 
or Fischer Exact where appropriate. Significance was defined as p< 0.05. 
Comparison of normal ultrasound to abnormal ultrasound was based on the 
following maternal demographic components: age, advanced maternal age (age > 
35 years), diabetes, weight, estimated gestational age (EGA) at ultrasound, EGA 
at triple screen, and triple screen risk. Assessment o f neonatal data included the 
percentage undergoing amniocentesis, the percentage o f aneuploidies, and the
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percentage o f trisomy 18. Results o f  this data are shown in Table 1 and Table 2, 
respectively (See Appendix A). Data analysis was provided by Justine Ritchie, 
Assistant Professor o f Mathematics and Statistics at Grand Valley State 
University.
Characteristics o f Subiects 
Differences in the maternal data were not significant in any o f the 
categories except weight distribution. The mean weight for the normal ultrasound 
group was 158.1 pounds as compared to 143.1 pound for the abnormal ultrasound 
group (p <0.03). The results o f the neonatal data demonstrate statistically 
significant differences between the normal and abnormal ultrasound groups. The 
total number o f aneuploidies detected in the study was 10. The percentage o f 
aneuploidy was 38.1% in the abnormal group and 2.5% in the normal group. 
Among the 8 aneuploidies with abnormal ultrasounds, there were 4 that were 
found to be trisomy 18. The other aneuploidies visualized on ultrasound consisted 
o f 1 case o f trisomy 16, 46 XX 9ph, 46 XX 4p-, and 1 triploidy. The two 
aneuploidies with normal ultrasounds were karyotyped as 46XX with an inversion 
o f 1 Iq and 47XYY. No cases o f trisomy 18 were found in the normal ultrasound 
group, where as all 4 cases o f trisomy 18 were found in the abnormal ultrasound 
group (p <0.001).
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CHAPTER FIVE 
DISCUSSION AND IMPLICATIONS
Discussion of Findings 
Analysis o f maternal data demonstrates that the only characteristic 
significantly different between the two identified groups is that o f weight 
distribution. One may argue that, in theory, ultrasound is more difficult to perform 
and evaluate on larger women due to poor visualization o f fetal anatomy. In our 
study, however, no cases o f trisomy 18 were missed on ultrasound. According to 
the results of the neonatal data, a higher percentage o f amniocentesis procedures 
were performed in the abnormal compared to the normal set. This is an expected 
outcome in that many o f those having an abnormal test typically pursue further 
evaluation. A majority o f the aneuploidies had detectable abnormalities 
visualized on ultrasound. All o f the trisomy 18 cases had abnormalities that were 
detected on ultrasound. Four other aneuploidies were identified on ultrasound. 
These consisted o f 1 case o f trisomy 16,1 case o f female with 46 chromosomes 
with an abnormality o f the heterochromatin on the short arm o f  chromosome 9, 1 
case o f a female with 46 chromosomes with a deletion on the short arm of 
chromosme 4, and 1 case o f  triploidy. Two aneuploidies, 46XX with an inversion 
o f chromosome 1 Iq and 47XYY, did not present with abnormalities on 
ultrasoimd. Both o f these are considered minor chromosome abnormalities and 
are not expected to be detected on ultrasound.
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Application o f Practice 
The results o f our study potentially will affect the genetic counseling of 
women at high risk for trisomy 18 as defined by triple marker screen. We hope to 
provide those women who screen positive for trisomy 18, yet have normal 
ultrasound results, the ability to make a more informed decision about 
amniocentesis based on their adjusted risk. Although amniocentesis is a definitive 
test for the determination o f chromosomal abnormalities, it is not without risk. In 
theory, the application o f our data in a clinical setting would lead to a  reduction in 
the number of amniocenteses performed on women with normal fetal ultrasounds.
Limitations and Recommendations 
Limitations of this study include the size of our sample population and a 
limited number of trisomy 18 cases within this population. Complete data was 
unable to be recovered as this information was contained in patient charts located 
in various offices throughout Michigan. Due to the fact that this study was non­
randomized, we are unable to extend our findings to the general population.
Before the results o f  this study can be implemented into clinical practice, 
further studies targeting a larger population will lend itself to the reliability of this 
study. Furthermore, a prospective study following a population at increased risk 
for trisomy 18 based on triple marker screen will minimize amount o f  incomplete 
data. Additional studies are needed that focus on the detection o f trisomy 18 
using non-invasive procedures.
40
Conclusions
The purpose of this study was to determine whether the risk of trisomy 18 
in women who screened positive for trisomy 18 yet had normal ultrasound results 
was less than the procedure-related risk o f amniocentesis. In other words, is the 
risk o f amniocentesis-related loss greater than the risk o f having a trisomy 18 
fetus? We found in our study population that the presence o f normal ultrasound 
findings is not associated with an increased risk o f  trisomy 18. The analyzed data 
showed that women with a positive triple screen but a normal ultrasound were at 
significantly less risk of actually having a trisomy 18 fetus than the women with 
abnormal ultrasounds. Furthermore, abnormal ultrasound findings are 
significantly associated with an increased risk o f trisomy 18 and other 
aneuploidies. All cases of trisomy 18 in this study population had an abnormal 
ultrasound. Therefore, amniocentesis for all positive triple screens in this study 
population is not justified for the identification o f affected infants.
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APPENDIX A 
Data Tables
Table 1 
Maternai Demographic Data: Comparison of patients with 
positive triple marker serum screen for trisomy 18
Demographic
Data
Normal
Ultrasound
Group
Abnormal
Ultrasound
Group
Statistical
Significance*
Age* (years) 31.0 29.7 NS
AMA^ (%) 34.7 22.7 NS
Weight^ (lbs) 158.1 143.1 p <0.03
DM^ (%) 2.0 4.5 NS
EGAatTS*
(wks)
17.6 17.9 NS
EGA at US'* 
(wks)
20.6 19.8 NS
TS Risk^ 1:130 1:103 NS
* Statistical significance defined as p <0.05
1. Mean age o f subjects in years
2. % o f subjects with advanced maternal age (age >35)
3. Mean weight of subjects in pounds
4. % o f subjects with diabetes mellitus
5. Mean estimated gestational age at triple screen
6. Mean estimated gestational age at ultrasound
7. Mean calculated triple screen risk ratio
Table 2 
Neonatal Data: Comparison of fetal data from pregnant women 
with a positive triple marker serum screen for trisomy 18
Demographic Data Normal
Ultrasound
Group
Abnormal
Ultrasound
Group
Statistical
Significance*
Amniocentesis* (%) 31.9 68.2 P <0.002
Trisomy 18"* (%) 0 19 P <0.001
Aneuploidy^ (%) 2.5»* 38.1 P <0.001
* Statistical significance is defined as p <0.05
**2.5%(n=2) o f the fetuses in the nonnal ultrasound group had some type of 
aneuploidy. However, these aneuploidies were not significant as fetal outcome is 
expected to be good. Furthermore, no abnormalities from these two aneuploidies 
are expected to be detected on ultrasound.
1. % o f subjects who had amniocentesis performed
2. % o f fetuses actually having trisomy 18
3. % o f fetuses with aneuploidy as determined by amniocentesis
APPENDIX B 
Data Collection Forms
F^ atiant MR Numocr" Nam#
OalaShMl
PatiMt Agt Weight Race Parity Dlal>etee EGAatTS DateTS TSRIek B-HCG AFP Eetifol EGA at US Date US
OtIaShM l
Echog#mlc bowel Abd. wall 
defect
Other abnl. BPD AC FL RL Amnlocenteels Résulta Pediatric
follow up
(If no amnio)
OatoShMl
Nuchal
thicknest
>6mm
Renal
pyeleclatis
>4mm
cardiac defect type cardiac defect Umbe < 5% Choroid
plexus
cyst
SUA Abnl hands Abnl feet
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